Del Mar Pharmaceuticals and Guangxi Wuzhou Pharmaceutical have teamed up for the global development of DAG for Injection (VAL-083), a chemotherapy which is already approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Wuzhou manufactures and sells VAL-083 in China for the approved indications, and Del Mar is carrying out clinical trials in the U.S. evaluating the drug as a potential treatment for glioblastoma. The firm is also working to demonstrate the utility of DAG for Injection against refractory cancers, including sub-types of CML and lung cancer that are refractory to tyrosine kinase inhibitors.
Under terms of the new collaboration Wuzhou and Del Mar will use Del Mar’s clinical and research data to expand the market for the drug in China, and achieve regulatory approval of VAL-083 for multiple indications, globally. Wuzhou will act as the exclusive supplier of DAG for Injection, and will provide financial and other support for Del Mar to start clinical development in China as part of an international clinical development program.
Del Mar will take responsibility for development and commercialization the drug in non-Chinese markets, and will share clinical and nonclinical data to aid Wuzhou obtain approval in China for new indications, including glioblastoma multiforme. The firms will also work together to achieve FDA certification of Wuzhou as a cGMP manufacturer of DAG for Injection.